

ASCO 2019 Annual Meeting

McCormick Place, Chicago, IL, May 31 – June 4, 2019

Plenary			
Authors	Title	Abstract #	Date/Time
William D. Tap, Andrew J. Wagner, Zsuzsanna Papai, Kristen N. Ganjoo, Chueh-Chuan Yen, Patrick Schoffski, Albiruni Ryan Abdul Razak, Javier Martin Broto, Alexander I. Spira , Akira Kawai, Anders Krarup-Hansen, Axel Le Cesne, Brian Van Tine, Yoichi Naito, Se Hoon Park, Victoria Soldatenkova, Gary Mo, Ashwin Shahir, Jennifer Wright, Robin Lewis Jones	ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS).	Abstract # LBA3	Sunday, June 2, 1:00 PM to 4:00 PM; Hall B1
Orals			
Authors	Title	Abstract #	Date/Time
Bijal D. Shah, Michael Russell Bishop, Olalekan O. Oluwole, Aaron Logan, Maria R. Baer, William Bruce Donnellan, Kristen Marie Carr-O'Dwyer, Houston Holmes , Martha Lucia Arellano, Armin Ghobadi, John M. Pagel, Yi Lin, Ryan Daniel Cassaday, Jae Hong Park, Armen Mardiros, Tong Shen, Lovely Goyal, Remus Vezan, Rajul K. Jain, William G. Wierda	End of phase I results of ZUMA-3, a phase 1/2 study of KTE-X19, anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in adult patients (pts) with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).	Abstract # 7006	Saturday, June 1, 3:00 PM to 6:00 PM; E451
Pasi A. Janne, Joel W. Neal, D. Ross Camidge, Alexander I. Spira , Zofia Piotrowska, Leora Horn, Daniel Botelho Costa, Anne S. Tsao, Jyoti D. Patel, Shirish M. Gadgeel, Lyudmila Bazhenova, Viola Weijia Zhu, Howard West, Sylvie Vincent, Jian Zhu, Shuanglian Li, Gregory J. Riely	Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions.	Abstract # 9007	Monday, June 3, 8:00 AM to 11:00 AM; Hall B1
George D. Demetri, Jason J. Luke, Antoine Hollebecque, John D. Powderly, Alexander I. Spira , Vivek Subbiah, Dominic W. Lai, Huibin Yue, Sreeneeranj Kasichayanula, Scott Gulbranson, James Purcell, Melinda Myzak, Randy Robinson, Victor Manuel Villalobos, Anthony W. Tolcher	First-in-human phase 1 study of ABBV-085, an antibody-drug conjugate (ADC) targeting LRRC15, in sarcomas and other advanced solid tumors.	Abstract # 8012	Monday, June 3, 8:00 AM to 11:00 AM; S406
Matt D. Galsky, Sumanta K. Pal, Amir Mortazavi, Matthew I. Milowsky, Saby George, Sumati Gupta, Mark T. Fleming , Long H. Dang, Daniel M. Geynisman, Radhika Walling, Robert S. Alter, Erwin L. Robin, Jue Wang, Shilpa Gupta, David D. Chism, Joel Picus, George Philips, David I. Quinn, Noah M. Hahn, Menggang Yu	Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (mUC): HCRN GU14-182.	Abstract # 4504	Monday, June 3, 8:00 AM to 11:00 AM; Arie Crown Theater
Nathan Hale Fowler, Felipe Samaniego, Wojciech Jurczak, Ewa Lech-Maranda, Nilanjan Ghosh, Piers Patten, James Andrew Reeves, Lori Ann Leslie, Julio C. Chavez, Paolo Ghia, Corrado Tarella, John M. Burke, Jeff Porter Sharman, Kathryn Kolibaba , Owen A. O'Connor, Chan Cheah, Hari P. Miskin, Peter Sportelli, Michael S. Weiss, Pier Luigi Zinzani	Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: A multicenter, open label, registration directed phase II study.	Abstract # 7506	Tuesday, June 4, 9:45 AM to 12:45 PM; E451

Poster Discussions			
Authors	Title	Abstract #	Date/Time
Aung Naing, Fiona C. Thistlethwaite, Alexander I. Spira , Javier Garcia-Corbacho, Manreet Randhawa, Ferry Eskens, Bert O'Neil, Javier Lavernia, Nataliya Volodymyrivna Uboha, Omid Hamid, Anthony B. El-Khoueiry, Beverly A. Benson, William Garner, Vanessa Jessica Huels, Hendrik-Tobias Arkenau, Patricia LoRusso	CX-072, a PD-L1 Probody therapeutic, as monotherapy in patients with advanced solid tumors: Preliminary results of PROCLAIM-CX-072.	Abstract # 2513	Saturday, June 1 1:15 PM to 2:45 PM; Hall D1
D. Ross Camidge, Fabrice Barlesi, Jonathan Wade Goldman, Daniel Morgensztern, Rebecca Suk Heist, Everett E. Vokes, Alexander I. Spira , Eric Angevin, Wu-Chou Su, David S. Hong, John H. Strickler, Monica Motwani, Zhaowen Sun, Apurvasena Parikh, Elysa Noon, Jun Wu, Karen Kelly	Results of the phase 1b study of ABBV-399 (telisotuzumab vedotin; teliso-v) in combination with erlotinib in patients with c-Met+ non-small cell lung cancer by EGFR mutation status.	Abstract # 3011	Saturday, June 1 3:00 PM to 4:30 PM; E450
Barbara K Haas, Cynthia R. C. Osborne , Svetislava J. Vukelja , Jennifer Selman, Trevor Davis, Gary T. Kimmel	Optimizing Breast Cancer Care Across the Continuum Neelima Denduluri, MD , Discussant The US Oncology Network	Abstracts # 6524 6525 6526	Saturday, June 1 4:30 PM to 6:00 PM; S102
Christopher Sweeney, Ivor John Percent, Sunil Babu, Jennifer Cultrera, Bryan Allyn Mehlhaff, Oscar B. Goodman , David Morris, Ian D. Schnadig , Costantine Albany, Neal D. Shore, Paul R Sieber, Susan Guba, Minmin Wang, Suhyun Kang, Volker Wacheck, Gregory P Donoho, Anna M. Szpurka, Sophie Callies, Boris K. Lin, Johanna C. Bendell	Phase 1b/2 study of enzalutamide (ENZ) with LY3023414 (LY) or placebo (PL) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) after progression on abiraterone.	Abstract # 5009	Saturday, June 1 4:30 PM to 6:00 PM; Arie Crown Theater
Otto Metzger Filho, Daniel G. Stover, Sarah Asad, Peter J Ansell, Mark Watson, Sibylle Loibl, Charles E. Geyer, Joyce O'Shaughnessy , Michael Untch, Hope S. Rugo, Jens Bodo Huober, Mehra Golshan, William M. Sikov, Gunter Von Minckwitz, Priya Rastogi, David Maag, Norman Wolmark, Carsten Denkert, William Fraser Symmans	Immunophenotype and proliferation to predict for response to neoadjuvant chemotherapy in TNBC: Results from BrighTNess phase III study.	Abstract # 510	Sunday, June 2 4:30 PM to 6:00 PM; Hall D2
Mark A. Socinski, Robert M. Jotte , Federico Cappuzzo, Tony S. K. Mok, Howard West, Makoto Nishio, Vassiliki Papadimitrakopoulou, Francisco J Orlandi, Daniil Stroyakovskiy, Christian A. Thomas, Naoyuki Nogami, Fabrice Barlesi, Anthony Lee, Geetha Shankar, Wei Yu, Marcus Ballinger, Ilze Bara, Alan Sandler, Martin Reck	IMpower150: Analysis of efficacy in patients (pts) with liver metastases (mets).	Abstract # 9012	Sunday, June 2 4:30 PM to 6:00 PM; Hall D1
David Jacob Andorsky , Morton Coleman, Abdurraheem Yacoub, Jason M. Melear , Suzanne R. Fanning , Kathryn Kolibaba , Frederick Lansigan, Chris Reynolds, Kenneth A. Foon, Jiahui Li, Mary Llorente, Mathias J. Rummel, Jeff Porter Sharman	MAGNIFY: Phase IIIb interim analysis of induction R2 followed by maintenance in relapsed/refractory indolent non-Hodgkin lymphoma.	Abstract # 7513	Monday, June 3 11:30 AM to 1:00 PM; E450
William Bensinger, Anastasios Raptis, James R. Berenson, Alexander I. Spira , Ajay K. Nooka, Maria Chaudhry, Peter van Zandvoort, Nitya Nair, Jeannette Lo, Jeroen Elassaiss-Schaap, Jackie Walling, Parameswaran Hari	Safety and tolerability of BION-1301 in adults with relapsed or refractory multiple myeloma.	Abstract # 8012	Monday, June 3 1:15 PM to 2:45 PM; E450
Hamid Enamekhoo, Mark Olsen, Bradley Curtis Carthon, Alexandra Drakaki, Ivor John Percent, Ana M. Molina, Daniel C. Cho, Johanna C. Bendell, Lucio N. Gordan, Arash Rezazadeh Kalebasty, Daniel J. George, Thomas E. Hutson , Richard J. Lee, Tina C. Young, Jennifer Johansen, Scott S. Tykodi	Safety and efficacy of nivolumab plus ipilimumab (NIVO+IPI) in patients with advanced renal cell carcinoma (aRCC) with brain metastases: Interim analysis of CheckMate 920.	Abstract # 4517	Monday, June 3 4:30 PM to 6:00 PM; Hall D2

Poster Presentations			
Authors	Title	Abstract #	Date/Time
Minetta C. Liu, Arash Jamshidi, Oliver Venn, Alexander P. Fields, M. Cyrus Maher, Gordon Cann, Hamed Amini, Samuel Gross, Joerg Bredno, Meredith Miller, Jan Schellenberger, Kathryn N. Kurtzman, Eric T. Fung, Tara Maddala, Geoffrey R. Oxnard, Eric A. Klein, David R. Spiegel, Anne-Renee Hartman, Alex Aravanis, Michael Seiden	Genome-wide cell-free DNA (cfDNA) methylation signatures and effect on tissue of origin (TOO) performance.	Abstract # 3049	Saturday, June 1 8:00 AM to 11:00 AM; Hall A
Spyro Mousses, David Schneider, Jeff Kiefer, Pieter Derdeyn, Kendyl Douglas, Abhishek Kothari, Daniel D. Von Hoff , Chris Yoo	Application of artificial intelligence to predict a new class of novel synthetic lethal targets.	Abstract # 2598	Saturday, June 1 8:00 AM to 11:00 AM; Hall A
Carlos Roberto Becerra , Gulam Abbas Manji, Dae Won Kim, Olivia Gardner, Aditya Malankar, Joanne Shaw, Devin Blass, Xiaohui Yi, Aaron E. Foster, Paul Woodard	Ligand-inducible, prostate stem cell antigen (PSCA)-directed GoCAR-T cells in advanced solid tumors: Preliminary results with cyclophosphamide (Cy) ± fludarabine (Flu) lymphodepletion (LD).	Abstract # 2536	Saturday, June 1 8:00 AM to 11:00 AM; Hall A
Amir A. Jazaeri, Emese Zsiros, Rodabe Navroze Amaria, Andrew S. Artz, Robert P. Edwards, Robert Michael Wenham, Brian M. Slomovitz, Axel Walther, Sajeve Samuel Thomas, Jason Alan Chesney, Robert Morris, Koji Matsuo, Stephanie Gaillard, Peter Graham Rose, Jesus Garcia Donas, Jacqueline Maria Tromp, Fatemeh Tavakkoli, Huiling Li, Maria Fardis, Bradley J. Monk	Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma.	Abstract # 2538	Saturday, June 1 8:00 AM to 11:00 AM; Hall A
Abdul Rafah Naqash, Paul R. Walker, Mahvish Muzaffar, Rebecca Feldman, Maida Hafiz, Stephen V. Liu, Hirva Mamdani, Anokhi Patel, Hossein Borghaei, Nitika Sharma, Jorge J. Nieva, Yanis Bumber, Ari M. Vanderwalde, Patrick C. Ma, Ihab Eldessouki, David Craig Portnoy, Alexander I. Spira , Li V. Yang, Nagla Fawzy Abdel Karim	Tumor mutational burden (TMB) profile of K-RAS/TP-53 co-mutation in metastatic non-small cell lung cancer (m-NSCLC).	Abstract # 2626	Saturday, June 1 8:00 AM to 11:00 AM; Hall A
Aung Naing, Fiona C. Thistlethwaite, Alexander I. Spira , Javier Garcia-Corbacho, Manreet Randhawa, Ferry Eskens, Bert O'Neil, Javier Lavernia, Nataliya Volodymyrivna Uboha, Omid Hamid, Anthony B. El-Khoueiry, Beverly A. Benson, William Garner, Vanessa Jessica Huels, Hendrik-Tobias Arkenau, Patricia LoRusso	CX-072, a PD-L1 Probody therapeutic, as monotherapy in patients with advanced solid tumors: Preliminary results of PROCLAIM-CX-072.	Abstract # 2513	Saturday, June 1 8:00 AM to 11:00 AM; Hall A
D. Ross Camidge, Fabrice Barlesi, Jonathan Wade Goldman, Daniel Morgensztern, Rebecca Suk Heist, Everett E. Vokes, Alexander I. Spira , Eric Angevin, Wu-Chou Su, David S. Hong, John H. Strickler, Monica Motwani, Zhaowen Sun, Apurvasena Parikh, Elysa Noon, Jun Wu, Karen Kelly	Results of the phase 1b study of ABBV-399 (telisotuzumab vedotin; teliso-v) in combination with erlotinib in patients with c-Met+ non-small cell lung cancer by EGFR mutation status.	Abstract # 3011	Saturday, June 1 8:00 AM to 11:00 AM; Hall A
Lalan S. Wilfong , Jody S. Garey, Bo He, Jad Hayes, Hope Ives, Susan Nga Hoang, Marcus A. Neubauer	Clinical and economic outcomes of pegfilgrastim in metastatic colorectal cancer.	Abstract # 6636	Saturday, June 1 1:15 PM to 4:15 PM; Hall A
Allen Lee Cohn , Michael Seiden , Kathryn N. Kurtzman, Earl Hubbell, Samuel Gross, Oliver Venn, Eric T. Fung, Minetta C. Liu, Eric A. Klein, Geoffrey R. Oxnard, Anne-Renee Hartman, David Michael Waterhouse	The Circulating Cell-free Genome Atlas (CCGA) Study: Follow-up (F/U) on non-cancer participants with cancer-like cell-free DNA signals.	Abstract # 5574	Saturday, June 1 1:15 PM to 4:15 PM; Hall A
Barbara K Haas, Cynthia R. C. Osborne , Svetislava J. Vukelja , Jennifer Selman, Trevor Davis, Gary T. Kimmel	Effect of exercise during adjuvant chemotherapy for breast cancer.	Abstract # 6524	Saturday, June 1 1:15 PM to 4:15 PM; Hall A
Mary-Ellen Taplin, Martin Gleave, Christopher P. Evans, Eleni Efstathiou, Philip W. Kantoff, Ashley Ross , Neal D. Shore, Alberto Briganti, Boris A. Hadaschik, Axel Heidenreich, Oliver Brendan Rooney, Shaozhou Ken Tian, Lisa Wetherhold, Weichun Xu, Shinta Cheng, Adam S. Kibel	PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC).	Abstract # TPS5100	Saturday, June 1 1:15 PM to 4:15 PM; Hall A

Poster Presentations			
Authors	Title	Abstract #	Date/Time
Ignace Vergote, Florian Heitz, Paul Buderath, Matthew A. Powell, Jalid Sehouli, Christine M. Lee , Anne L. Hamilton, James Fiorica, Kathleen N. Moore, Michael Teneriello, Lisa Golden, Wei Zhang, Celine Pitou, Daphne L. Farrington, Katherine M Bell-McGuinn, Robert Michael Wenham	A randomized, double-blind, placebo-controlled phase Ib/II study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine (G) and carboplatin (C) versus GC for women with recurrent platinum-sensitive ovarian cancer.	Abstract # 5537	Saturday, June 1 1:15 PM to 4:15 PM; Hall A
Christopher Sweeney, Ivor John Percent, Sunil Babu, Jennifer Cultrera, Bryan Allyn Mehlhaff, Oscar B. Goodman , David Morris, Ian D. Schnadig , Costantine Albany, Neal D. Shore, Paul R Sieber, Susan Guba, Minmin Wang, Suhyun Kang, Volker Wacheck, Gregory P Donoho, Anna M. Szpurka, Sophie Callies, Boris K. Lin, Johanna C. Bendell	Phase Ib/2 study of enzalutamide (ENZ) with LY3023414 (LY) or placebo (PL) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) after progression on abiraterone.	Abstract # 5009	Saturday, June 1 1:15 PM to 4:15 PM; Hall A
Juliet Elizabeth Wolford, Krishnansu Sujata Tewari, Su-Ying Liang, Jiaru Bai, Amandeep Kaur Mann, Kathleen N. Moore, Eric Pujade-Lauraine, Jonathan A. Ledermann, Bradley J. Monk , John K. Chan	SOLO1 versus SOLO2: Cost-effectiveness of olaparib as maintenance therapy for newly diagnosed and platinum-sensitive recurrent ovarian carcinoma among women with germline BRCA mutations (gBRCAmut).	Abstract # 5545	Saturday, June 1 1:15 PM to 4:15 PM; Hall A
Bradley J. Monk , Jyoti Mayadev, Ana T Nunes, Alicja Dabrowska Brown, Michelle Marcovitz, Mark C. Lanasa	CALLA: Efficacy and safety of durvalumab with and following concurrent chemoradiotherapy (CCRT) versus CCRT alone in women with locally advanced cervical cancer: A phase III, randomized, double-blind, multicenter study.	Abstract # TPS5597	Saturday, June 1 1:15 PM to 4:15 PM; Hall A
Ronnie Shapira-Frommer, Jerome Alexandre, Bradley Monk , Tanja N. Fehm, Nicoletta Colombo, Maria V. Caceres, Kosei Hasegawa, Coraline Dubot, Jerry Jing Li, Karen Stein, Stephen Michael Keefe, Krishnansu Sujata Tewari; Sheba Medical Center, Ramat-Gan, Israel	KEYNOTE-826: a phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer.	Abstract # TPS5595	Saturday, June 1 1:15 PM to 4:15 PM; Hall A
A. Oliver Sartor, Andrew J. Armstrong, Chiledum Ahaghotu, David G. McLeod, Matthew R. Cooperberg, David F. Penson, Philip W. Kantoff, Nicholas J. Vogelzang , Arif Hussain, Christopher Michael Pieczonka, Neal D. Shore, David I. Quinn, Eric Jay Small, Elisabeth I. Heath, Ronald F Tutrone, Paul F. Schellhammer, Matthew Harmon, Nancy N. Chang, Stephen J. Freedland, Celestia S. Higano	Overall survival (OS) of African-American (AA) and Caucasian (CAU) men who received sipuleucel-T for metastatic castration-resistant prostate cancer (mCRPC): Final PROCEED analysis.	Abstract # 5035	Saturday, June 1 1:15 PM to 4:15 PM; Hall A
Joyce O'Shaughnessy , Mario Campone, Fabrice Andre, Arnd Nusch, Eva-Maria Grischke, Cristian Villanueva, Norbert Marschner, Eric P. Winer, Shani Paluch-Shimon, Karen Rodriguez-Lorenc, Annie Hilliard, Fabienne Le Gac, Antonia Ridolfi, Gabriel N. Hortobagyi	First-line (1L) ribociclib (RIB) plus letrozole (LET) for postmenopausal women with hormone receptor-positive (HR+), HER2- advanced breast cancer (ABC): MONALEESA-2 long-term safety results.	Abstract # 1078	Sunday, June 2 8:00 AM to 11:00 AM; Hall A
Otto Metzger Filho, Daniel G. Stover, Sarah Asad, Peter J Ansell, Mark Watson, Sibylle Loibl, Charles E. Geyer, Joyce O'Shaughnessy , Michael Untch, Hope S. Rugo, Jens Bodo Huober, Mehra Golshan, William M. Sikov, Gunter Von Minckwitz, Priya Rastogi, David Maag, Norman Wolmark, Carsten Denkert, William Fraser Symmans	Immunophenotype and proliferation to predict for response to neoadjuvant chemotherapy in TNBC: Results from BrightNess phase III study.	Abstract # 510	Sunday, June 2 8:00 AM to 11:00 AM; Hall A
Seth Andrew Wander, Mark Zangardi, Andrzej Niemierko, Avinash Kambadakone, Leslie SL Kim, Jing Xi, Apurva Kumari Pandey, Laura Spring, Casey Stein, Dejan Juric, Irene Kuter, Beverly Moy, Therese Marie Mulvey, Neelima Vidula, Steven J. Isakoff, Megan Yuen, Adam Brufsky, Cynthia X. Ma, Joyce O'Shaughnessy , Aditya Bardia	A multicenter analysis of abemaciclib after progression on palbociclib in patients (pts) with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC).	Abstract # 1057	Sunday, June 2 8:00 AM to 11:00 AM; Hall A

Poster Presentations			
Authors	Title	Abstract #	Date/Time
Joyce O'Shaughnessy, Martine Piccart, Lee S. Schwartzberg, Javier Cortes, Nadia Harbeck, Seock-Ah Im, Hope S. Rugo, Michael Untch, Denise A. Yardley, Igor Bondarenko, Stephen Chan, Veronique Dieras, Mark D. Pegram, Stew Kroll, Joseph P. O'Connell, Jeff Vacirca, Thomas Wei, Kevin Tang, Andrew David Seidman	CONTESSA: A multinational, multicenter, randomized, phase III registration study of tasetaxel plus a reduced dose of capecitabine in patients (pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (LA/MBC) who have previously received a taxane.	Abstract # TPS1107	Sunday, June 2 8:00 AM to 11:00 AM; Hall A
Mark A. Socinski, Robert M. Jotte , Federico Cappuzzo, Tony S. K. Mok, Howard West, Makoto Nishio, Vassiliki Papadimitrakopoulou, Francisco J Orlandi, Daniil Stroyakovskiy, Christian A. Thomas, Naoyuki Nogami, Fabrice Barlesi, Anthony Lee, Geetha Shankar, Wei Yu, Marcus Ballinger, Ilze Bara, Alan Sandler, Martin Reck	Impower150: Analysis of efficacy in patients (pts) with liver metastases (mets).	Abstract # 9012	Sunday, June 2 8:00 AM to 11:00 AM; Hall A
Hyo S. Han, Carlos A. Alemany, Ursa Abigail Brown-Glaberman, Timothy J. Pluard, Rajni Sinha, Danielle Sterenberg, Kathy S. Albain, Reva K. Basho, David Biggs, Valentina Boni, Sami Diab, Michaela L. Tsai , Katherine Hanna Tkaczuk, Yinghui Wang, Zejing Wang, Jane Lowe Meisel	SGNLVA-002: Single-arm, open label phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer.	Abstract # TPS1110	Sunday, June 2 8:00 AM to 11:00 AM; Hall A
Hirva Mamdani, Jerry Chen, Seongho Kim, Yahya Ibrahim, Mohammad Fahad Bin Asad, Jorge J. Nieva, Rebecca Feldman, Abdul Rafah Naqash, Stephen V. Liu, Patrick C. Ma, David Craig Portnoy, Hossein Borghaei, Nagla Fawzy Abdel Karim, Yanis Boumber, Ari M. Vanderwalde, Alexander I. Spira , Shadia Ibrahim Jalal	DNA damage response and repair (DDR) gene mutations and correlation with tumor mutation burden (TMB) in non-small cell lung cancer (NSCLC).	Abstract # 9100	Sunday, June 2 8:00 AM to 11:00 AM; Hall A
Sami Diab , Hope S. Rugo, Lida A. Mina, Shannon Puhalla, Reshma L. Mahtani, Norah Lynn Henry, Neelima Denduluri , Denise A. Yardley, Yao Wang, Lillian Shahied Arruda, Iulia Cristina Tudor, Eric Roland Gauthier, Akos Gabor Czibere, Jennifer Keating Litton, Sara A. Hurvitz	Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2-germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study.	Abstract # 1044	Sunday, June 2 8:00 AM to 11:00 AM; Hall A
Jacob M. Sands, Toshio Shimizu, Edward B. Garon, Jonathan Greenberg, Ferdinand M. Guevara, Rebecca Suk Heist, Fumiaki Kobayashi, Yutaka Noguchi, Daisuke Okajima, Naoyuki Tajima, Alexander I. Spira , Noboru Yamamoto, Aaron Elliott Lisberg	First-in-human phase 1 study of DS-1062a in patients with advanced solid tumors.	Abstract # 9051	Sunday, June 2 8:00 AM to 11:00 AM; Hall A
Mark M. Awad, Yvan Le Bruchec, Brian Lu, Julieann Miller, Calin Dan Dumitru, Alexander I. Spira	Phase Ib study: Selective histone deacetylase (HDAC) inhibitor ACY-241 + nivolumab (Nivo) in advanced non-small cell lung cancer (NSCLC).	Abstract # 9092	Sunday, June 2 8:00 AM to 11:00 AM; Hall A
Cristina Gasparetto, Sundar Jagannath, Robert M. Rifkin , Brian G. Durie, Mohit Narang , Howard R. Terebelo, Kathleen Toomey, James W. Hardin, Lynne I. Wagner, Sikander Ailawadhi, James Omel, Hans Chulhee Lee, Shankar Srinivasan, Mazaher Dhalla, Donna Catamero, Amit Agarwal, Rafat Abonour	Effect of t(11;14) on outcomes of patients (pts) with newly diagnosed multiple myeloma (NDMM) in the connect MM registry.	Abstract # 8032	Monday, June 3 8:00 AM to 11:00 AM; Hall A
Herve Tilly, Christopher Flowers, Jonathan W. Friedberg, Charles Herbaux, Franck Morschhauser, Laurie Helen Sehn, Jeff Porter Sharman , Marek Trneny, Calvin Lee, Gilles A. Salles	POLARIX: A phase 3 study of polatuzumab vedotin (pola) plus R-CHP versus R-CHOP in patients (pts) with untreated DLBCL.	Abstract # TPS7571	Monday, June 3 8:00 AM to 11:00 AM; Hall A
Thomas E. Witzig, Kami J. Maddocks, Sven De Vos, Roger M. Lyons, William Jeffery Edenfield, Jeff Porter Sharman , Julie Vose, Habte Aragaw Yimer , Helen Wei, Edward M Chan, Priti Patel, Christopher Di Simone, Mitul Gandhi, Jennifer Vaughn, Kathryn Kolibaba , Bruce D. Cheson, Felipe Samaniego	Phase 1/2 trial of acalabrutinib plus pembrolizumab (Pem) in relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).	Abstract # 7519	Monday, June 3 8:00 AM to 11:00 AM; Hall A

Bolded text: Investigators associated with US Oncology Research, The US Oncology Network, and/or McKesson

Poster Presentations			
Authors	Title	Abstract #	Date/Time
Kerry Anne Rogers, Philip A. Thompson, John Nathan Allan, Morton Coleman, Jeff Porter Sharman , Bruce D. Cheson, Raquel Izumi, Melanie M. Frigault, Cheng Seok Quah, Rakesh K. Raman, Min Hui Wang, Thomas J. Kipps	Phase 2 study of acalabrutinib in ibrutinib (IBR)-intolerant patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).	Abstract # 7530	Monday, June 3 8:00 AM to 11:00 AM; Hall A
William Bensinger, Anastasios Raptis, James R. Berenson, Alexander I. Spira , Ajay K. Nooka, Maria Chaudhry, Peter van Zandvoort, Nitya Nair, Jeannette Lo, Jeroen Ellassaiss-Schaap, Jackie Walling, Parameswaran Hari	Safety and tolerability of BION-1301 in adults with relapsed or refractory multiple myeloma.	Abstract # 8012	Monday, June 3 8:00 AM to 11:00 AM; Hall A
David Jacob Andorsky , Morton Coleman, Abdulraheem Yacoub, Jason M. Melear , Suzanne R. Fanning , Kathryn Kolibaba , Frederick Lansigan, Chris Reynolds, Kenneth A. Foon, Jiahui Li, Mary Llorente, Mathias J. Rummel, Jeff Porter Sharman	MAGNIFY: Phase IIIb interim analysis of induction R2 followed by maintenance in relapsed/refractory indolent non-Hodgkin lymphoma.	Abstract # 7513	Monday, June 3 8:00 AM to 11:00 AM; Hall A
Hamid Eamekhoo, Mark Olsen, Bradley Curtis Carthon, Alexandra Drakaki, Ivor John Percent, Ana M. Molina, Daniel C. Cho, Johanna C. Bendell, Lucio N. Gordan, Arash Rezazadeh Kalebasty, Daniel J. George, Thomas E. Hutson , Richard J. Lee, Tina C. Young, Jennifer Johansen, Scott S. Tykodi	Safety and efficacy of nivolumab plus ipilimumab (NIVO+IPI) in patients with advanced renal cell carcinoma (aRCC) with brain metastases: Interim analysis of CheckMate 920.	Abstract # 4517	Monday, June 3 1:15 PM to 4:15 PM; Hall A
Camillo Porta, Elena Verzoni, Bernard Escudier, Sumanta K. Pal, Michael B. Atkins, Thomas E. Hutson, Michael N. Needle, David F. McDermott, Brian I. Rini	TIVO-3: Subgroup analysis of progression-free survival of tivozanib compared to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).	Abstract # 4572	Monday, June 3 1:15 PM to 4:15 PM; Hall A
J. Russell Hoverman , Cynthia B. Taniguchi, Jad Hayes, Kathryn Eagye, B. Brooke Mann, Marcus A. Neubauer	Unraveling the high cost of end-of-life care: An oncology care model experience.	Abstract # 11534	Monday, June 3 1:15 PM to 4:15 PM; Hall A
Geoffrey R. Oxnard, Xiaoji Chen, Eric T. Fung, Ting Ma, Jafi Lipson, Earl Hubbell, Kathryn N. Kurtzman, Shilpen Patel, Rita Shaknovich, Zhao Dong, Hai Liu, Jacqueline D. Brooks, David R. Spigel, Michael Seiden , Alex Aravanis, Eric A. Klein, Anne-Renee Hartman, Minetta C. Liu	Prognostic significance of blood-based cancer detection in plasma cell-free DNA (cfDNA): Evaluating risk of overdiagnosis.	Abstract # 1545	Monday, June 3 1:15 PM to 4:15 PM; Hall A
Mohammed M. Milhem, Georgina V. Long, Christopher J. Hoimes, Asim Amin, Christopher D. Lao, Robert Martin Conry, Jason Hunt, Gregory A. Daniels, Mohammed Almubarak, Montaser F. Shaheen, Theresa Michelle Medina, Minal A. Barve , Sarwan K. Bishnoi, Ehtesham A. Abdi, Michael Jon Chisamore, Biao Xing, Albert Candia, Erick Gamelin, Robert Janssen, Antoni Ribas	Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy.	Abstract # 9534	Monday, June 3 1:15 PM to 4:15 PM; Hall A
Asim Amin, Mohammed M. Milhem, Georgina V. Long, Christopher J. Hoimes, Theresa Michelle Medina, Robert Martin Conry, Christopher D. Lao, Gregory A. Daniels, Sunil A. Reddy, Robert Hans Ingemar Andtbacka, Minal A. Barve , Montaser F. Shaheen, Thomas Tueting, Michael Jon Chisamore, Emmett V. Schmidt, Albert Candia, Cynthia Chinedu Obiozor, Erick Gamelin, Robert Janssen, Antoni Ribas	Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced/metastatic melanoma resistant to anti-PD-1/PD-L1 therapy.	Abstract # 9555	Monday, June 3 1:15 PM to 4:15 PM; Hall A
Mario Mandalà, James M.G. Larkin, Paolo Antonio Ascierto, Michele Del Vecchio, Helen Gogas, C. Lance Cowey , ANA Maria Arance Fernandez, Stéphane Dalle, Michael Schenker, Jean Jacques Grob, Vanna Chiarion-Sileni, Ivan Marquez-Rodas, Marcus Butler, Anna Maria Di Giacomo, Mark R. Middleton, Jose Lutzky, Michael Millward, Veerle de Pril, Maurice Lobo, Jeffrey S. Weber	An analysis of nivolumab-mediated adverse events and association with clinical efficacy in resected stage III or IV melanoma (CheckMate 238).	Abstract # 9584	Monday, June 3 1:15 PM to 4:15 PM; Hall A

Publications		
Authors	Title	Abstract #
C. Lance Cowey, Nicholas J. Robert , Kalatu Davies, Janet L. Espirito, Jennifer R. Frytak, Israel Lowy, Matthew G. Fury	Treatment patterns and outcomes among patients with advanced cutaneous squamous cell carcinoma (CSCC) in a US community oncology setting.	Abstract #e21033
Marley Boyd, Srinivas Annavarapu, Gurjyot K. Doshi , Kentaro Imai, Eric Sbar, James Luke Godwin, Haojie Li, Guru Sonpavde	Real-world outcomes of metastatic urothelial carcinoma (mUC) patients (pts) treated with first or second-line immunotherapies (IO) in the United States (US).	Abstract # e16025
Michael Thomas, Nick Thatcher, Jerome H. Goldschmidt , Yuichiro Ohe, Helen McBride, Vladimir Hanes	Totality of evidence in development of the bevacizumab biosimilar ABP 215: Central and investigator evaluation of efficacy from the MAPLE study.	Abstract # e20708
Frankie Ann Holmes , Melissa Brammer, Renard Dubois, Feng Xu, Bin Yao, Deepa Lalla	Cumulative benefit of multiple agents and drug classes for adjuvant therapy (adj rx) of HER2+ early breast cancer (EBC).	Abstract # e12037
Priscilla Ontiveros, Maren K. Levin, Yipeng Wang, Beverly Hom, Ryan Dittamore, Joyce O'Shaughnessy	Imaging features of genomic instability in circulating tumor cells (CTCs) from metastatic triple-negative breast cancer (metTNBC) patients (pts) who received PIKTOR.	Abstract # e14527
Dana Meredith Chase, Brooke Harrow, Jessica Perhanidis, Bradley J. Monk	Gastrointestinal symptoms and diagnosis preceding ovarian cancer diagnosis: Delays in diagnosis and resulting effects on treatment allocation.	Abstract # e18195
Haider Mahdi, Peter Graham Rose, Fadi W Abdul-Karim, Bradley J. Monk , Ying Ni	The role of different TGFβ signatures in predicting outcome in high grade serous ovarian carcinoma.	Abstract # e14262
Haider Mahdi, Peter Graham Rose, Fadi W Abdul-Karim, Bradley J. Monk , Ying Ni	The role of proinflammatory immune (IFN-gamma) gene signature in predicting prognosis and response to chemotherapy in uterine carcinoma.	Abstract # e14209
Daniel Morgensztern, Michal G. Rose, John Charles Morris, Patrick C. Ma, Christina E. Brzezniak, Karen Grace Zeman, Arvinda Padmanabhan, JoAnn Hirth, Alexander I. Spira , Ellice Yuen-Ming Wong, Sukhmani Kaur Padda, Saiama Naheed Waqar	Multicenter phase II trial of RRx-001 in previously treated SCLC.	Abstract # e20104
Nagla Fawzy Abdel Karim, Chisom Onuoha, Imran Ahmad, Ihab Eldessouki, Patrick C. Ma, Rebecca Feldman, Hirva Mamdani, David Craig Portnoy, Alexander I. Spira , Stephen V. Liu, Abdul Rafeh Naqash	Correlation between K-RAS mutant subsets, TP53 mutation, and PD-L1 status in non-small cell lung cancer (NSCLC).	Abstract # e14272
William R. Berry, Christopher Michael Pieczonka, Nicholas J. Vogelzang , Lawrence Ivan Karsh, James L. Bailen, Krista Van Velzen, Harini Kandadi, Nadeem Anwar Sheikh, Shaker R. Dakhil	Antigen (Ag) spread after sipuleucel-T and correlation with overall survival (OS): A real-world experience	Abstract # e16504

Education Sessions		
Speaker	Title	Date/Time
Alexander I. Spira, MD, PhD, FACP	Meet the Professors: Optimal Sarcoma Care Outside of Large Academic Centers Sarcoma Management and Access to Clinical Trials in Independent Health Care Networks *ticketed session	Thursday June 1, 3:00 PM to 4:15 PM E253b

Learn More:

Online: usoncology.com/research

Email: researchopportunities@mckesson.com

Phone: (281) 863-1000